EDIT Editas Medicine Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EDIT

Price (delayed)

$2.98

Market cap

$291.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.17

Enterprise value

$240.09M

?
Relative Growth: Rel. Growth: 46
Relative Strength: Rel. Strength: 77
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 35

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a ...

Highlights
EDIT's EPS has surged by 62% year-on-year and by 35% since the previous quarter
Editas Medicine's net income has surged by 57% YoY and by 32% QoQ
Editas Medicine's quick ratio has decreased by 9% QoQ but it has increased by 4.6% YoY
Editas Medicine's gross profit has increased by 8% YoY but it has decreased by 4.5% from the previous quarter
EDIT's equity has dropped by 93% year-on-year and by 84% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.editasmedicine.com
Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of EDIT

EDIT stock price

How has the Editas Medicine stock price performed over time
Intraday
7.19%
1 week
-13.12%
1 month
-0.67%
1 year
63.74%
YTD
45.37%
QTD
20.65%

Financial performance

How have Editas Medicine's revenue and profit performed over time
Revenue
$38.69M
Gross profit
$38.69M
Operating income
-$108.85M
Net income
-$108.95M
Gross margin
100%
Net margin
-281.6%
EDIT's operating margin has surged by 61% year-on-year and by 29% since the previous quarter
The net margin has soared by 60% YoY and by 29% from the previous quarter
EDIT's operating income has soared by 58% year-on-year and by 32% since the previous quarter
Editas Medicine's net income has surged by 57% YoY and by 32% QoQ

Price vs fundamentals

How does EDIT's price correlate with its fundamentals

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation
P/E
N/A
P/B
66.17
P/S
7.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.2
EDIT's EPS has surged by 62% year-on-year and by 35% since the previous quarter
EDIT's P/B is 160% above its last 4 quarters average of 23.7
EDIT's equity has dropped by 93% year-on-year and by 84% since the previous quarter
The P/S is 72% less than the 5-year quarterly average of 25.4 but 26% more than the last 4 quarters average of 5.6
The revenue has grown by 8% year-on-year but it has declined by 4.5% since the previous quarter

Efficiency

How efficient is Editas Medicine business performance
EDIT's return on sales has surged by 61% year-on-year and by 29% since the previous quarter
EDIT's return on invested capital is down by 35% year-on-year but it is up by 11% since the previous quarter
The ROE has decreased by 29% from the previous quarter
Editas Medicine's ROA has increased by 24% YoY and by 22% from the previous quarter

Dividends

What is EDIT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time
EDIT's total assets is 3% higher than its total liabilities
EDIT's total assets is down by 43% YoY and by 20% QoQ
EDIT's total liabilities is down by 28% year-on-year and by 9% since the previous quarter
EDIT's equity has dropped by 93% year-on-year and by 84% since the previous quarter
The debt has contracted by 16% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.